ストックスクリーナーアプリを入手
6.00
30.15%
1.39
アフターアワーズ：
6.72
0.72
+12.00%
Jupiter Neurosciences Inc (JUNS) 最新ニュース
Jupiter Neurosciences Stock Short Interest Falls to 34.91% - Quiver Quantitative
A Tiny Psychedelic Stock Just Exploded Over 50% – Retail Traders Think $1 Is Next - Stocktwits
Stock Splits Calendar for: - Yahoo! Finance Canada
Calendrier des fractionnements d'actions pour: - Yahoo Finance France
Form 8K Jupiter Neurosciences Inc For: 6 August By Investing.com - Investing.com Nigeria
Jupiter Neurosciences Announces 1-for-75 Reverse Stock Split to Regain Nasdaq Compliance - Minichart
Jupiter Neurosciences Enacts 1-for-75 Reverse Stock Split - TipRanks
Jupiter Neurosciences Inc (JUNS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Jupiter Neurosciences executes 1-for-75 reverse stock split By Investing.com - Investing.com UK
Jupiter Neurosciences grants 472,222 director options | JUNS Insider Trading - Stock Titan
Jupiter Neurosciences executes 1-for-75 reverse stock split - Investing.com
Jupiter Neurosciences, Inc. Announces 1-for-75 Reverse Stock Split Effective August 6, 2026 - Quiver Quantitative
Jupiter Neurosciences, Inc. Announces Reverse Stock Split - GlobeNewswire
Jupiter Neurosciences announces 1-for-75 revers... - Pluang
Kaskela Law Firm Announces Stockholder Investigation of Jupiter N - The National Law Review
Jupiter Neurosciences expands into psychedelics with $100m deal - Longevity.Technology
Jupiter Neurosciences (Nasdaq: JUNS) sells 11.47M shares under SEPA - Stock Titan
Jupiter Neurosciences Inc (JUNS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Jupiter Neurosciences Stockholders Approve Key 2026 Actions - TipRanks
Jupiter Neurosciences, Inc. Files Form 8-K: Key Details on Nasdaq Listing, Address, and Corporate Status - Minichart
Jupiter Neurosciences (NASDAQ: JUNS) details Yorkville SEPA terms - Stock Titan
Jupiter Neurosciences Inc (JUNS) Cash Flow - TradingKey
Jupiter Neurosciences Inc (JUNS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Jupiter Neurosciences Inc (JUNS) Balance Sheet - TradingKey
Jupiter Neurosciences, Inc. Revenue Breakdown – NASDAQ:JUNS - TradingView
What is Driving Jupiter Neurosciences' Recent Stock Volatility - Kavout | AI
Jupiter Neurosciences Inc (JUNS) Institutional Confidence - TradingKey
Jupiter Neurosciences Expands CNS Pipeline with $100M ALA-002 Licensing DealEPS Surprise History - dars.gov.et
Psychedelic: PharmAla enters license agreement with Jupiter Neurosciences - TipRanks
Jupiter Neurosciences licenses MDMA drug in deal worth up to $100M - Dealroom
JUNS|Jupiter Neurosciences Inc|Price:0.148|Chg%:-0.005 - TradingKey
Jupiter Neurosciences director Andrew Jon Cutler files initial beneficial ownership statement - Bitget
Jupiter Neurosciences Secures Exclusive US Rights for ALA-002 - sekbernews.id
Psychedelic Therapy Meets M&A: Fireside Chat with Jupiter Neurosciences CEO Christer Rosén & President Alison Silva - Yahoo Finance
CNS drug specialist Jupiter Neuro signs MDMA deal with PharmAla Biotech - Mugglehead Investment Magazine
Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 - EIN Presswire
Jupiter Neurosciences acquires US rights to ALA-002 in deal worth up to $100M - MSN
Jupiter Neurosciences licenses MDMA drug ALA-002 - BioXconomy
PharmAla Biotech Licenses Lead Candidate ALA-002 to Jupiter Neuroscience in the US - Moomoo
Jupiter Neurosciences signs ALA-002 license agreement worth up to $100 million (NASDAQ:JUNS) - MSN
Jupiter Neurosciences expands CNS pipeline with $100 million PharmAla MDMA deal - The Pharma Letter
PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002 - Investing News Network
Jupiter Neurosciences Licenses ALA-002 for U.S. Development - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
Jupiter Neurosciences (Nasdaq: JUNS) to license ALA-002 in US - Stock Titan
Jupiter Neurosciences Stock (JUNS) Jumps on a New License Deal - TipRanks
Jupiter Neurosciences (NASDAQ:JUNS) surge cools as $100 million MDMA agreement strains funding resources - TechStock²
Tuesday's session: most active stocks - ChartMill
Jupiter Neurosciences Signs ALA-002 License Agreement Worth Up to $100 Million (NASDAQ:JUNS) - Yahoo Finance
Jupiter enters psychedelics space with $100M deal for MDMA drug - Fierce Biotech
PharmAla Biotech Grants Jupiter Neurosciences Exclusive U.S. Rights to ALA-002 in $100M Licensing Deal - Kalkine Media
PharmAla licenses ALA-002 drug to Jupiter for US market By Investing.com - Investing.com South Africa
PharmAla Biotech Holdings Inc. Grants Jupiter Neurosciences, Inc. Exclusive U.S. Rights To ALA-002 - marketscreener.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
PharmAla licenses ALA-002 drug to Jupiter for US market - Investing.com
Jupiter Neurosciences Enters License Agreement for Exclusive U.S. Rights to ALA-002, Expanding CNS Pipeline to Two Clinical-Stage Programs - Quiver Quantitative
Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million - Yahoo Finance
stop loss 0.5 🥲 - Moomoo
PharmAla Biotech Executes Definitive License Agreement - GlobeNewswire
PharmAla Retains ALA-002 Rights Outside U.S. in Jupiter License - Stock Titan
0.03%
0.33%
大文字化:
|
ボリューム (24 時間):